Welcome to the Celgene REMS Program

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID® (thalidomide), REVLIMID® (lenalidomide) and POMALYST® (pomalidomide). The THALOMID REMS program (formerly known as the S.T.E.P.S.® program), REVLIMID REMS program (formerly known as the RevAssist® program) and POMALYST REMS program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Celgene REMS programs, please click on the program name below:
Visit www.REVLIMIDREMS.com, to learn more about the REVLIMID REMS program.
Visit www.POMALYSTREMS.com, to learn more about the POMALYST REMS program.
Visit www.THALOMIDREMS.com, to learn more about the THALOMID REMS program.

For prescribers, please enter your User Name and Password to manage your patients through a Celgene REMS program. If you do not have an online account, select Create User Account to establish an account. Patients currently enrolled in a Celgene REMS program are not required to create an online account to complete a survey. Please select Patient Surveys and enter the information requested to begin a survey.

 
To login to your account:
User Name
Password
Forgot Password?